



Anne Cambon-Thomsen was educated in Toulouse, where she was born. Director of research at CNRS since 1988 (emeritus research director since 2015), she is MD, specialised in human immunogenetics; she holds degrees in human biology (immunohaematology option) in medical statistics and in health ethics. She has co-directed and coordinated the European Common Service ELSI (Ethical, legal, social implications) of the European infrastructure of

the European infrastructure "Biobanking and biomolecular resources research infrastructure (BBMRI-ERIC; <http://bbmri-eric.eu/common-services>) [02/2015 – 04/2017]. Her research work research is conducted in a joint unit Inserm-University Toulouse III Paul Sabatier in epidemiology and public health analyses in Toulouse (UMR 1027; www.u1027.inserm.fr) in the team of Emmanuelle Rial-Sebbag, entitled "Health innovations trajectories: bioethical issues and public health impact", team that she had previously established and directed under the title "Genomics, biotherapy and public health: interdisciplinary approach". She is the founder of the societal platform of the GIS Genotoul (<http://societal.genotoul.fr/>), where she continues to be an active member. She is presently Champion ESOF 2018 (EuroScience Open Forum), member of the European Group on ethics of science and new technologies (EGE, nomination 2017) and co-pilot of a working group of the French genomic medicine plan.

Previously, she began her career as a researcher at Inserm (1976-1988), and after a post-doctorate in Denmark in the early 80s, she led two research units between 1985 and 1997 at the University Hospital in Toulouse Purpan (Inserm unit and a CNRS unit, including 4 years of double-direction) on immunology research themes, immunopathology, transplantation, population genetics and genetic epidemiology of complex diseases. Her research focused on human genetic diversity and health issues, including the major histocompatibility complex and its medical applications. With over 250 publications in the fields of human immunogenetics, transplantation, population genetics, epidemiological genetics and bioethics since 1998, she has worked in recent years on societal and ethical aspects of biobanks, biotherapy, biotechnology, particularly genetic testing and sequencing as well as immunogenetics of complex diseases such as rheumatoid arthritis and the organization of transplantation in the health system. Bioethics dimensions as part of the governance of biomedical research and public health and health care decision making, cuts across all of her current work. Responsible for ethical and societal aspects of several European projects on biobanks and high throughput genomics in various scientific and clinical settings, and a founding member of the international collaboration platform ELSI2.0 she leads the international initiative BRIF (Bioresource research impact factor) that aims to build and develop a system to recognize and value the specific contribution of bioresources to research. She is a former member of the CCNE (French National Consultative Committee on Ethics in life sciences and health), the European Group on Ethics in Science and New Technologies (where she was again appointed in 2017), the PPPC (Public and professional policy committee) of the European society of human genetics and the ethics Committee of the project "Toulouse White Biotechnology" (TWB); she chaired from 1986 to 2011 the COPé (Operational Committee of Ethics in the life sciences at CNRS) of which she was a member from 1995 to 2002) and from 2011 to 2016 she was expert for the COMETS (Ethics Committee of CNRS). She is also Chair of the deontology and ethics Committee of the INCA (National Cancer Institute) and member of the ethics and deontology Committee of the French Blood Establishment (EFS), the National Blood Bank institute. She is also member of the "ethics and policy" Committee (EPC) of the international consortium of cancer genomics for medicine (ICGCmed) and of the Management Board of MURS (universal movement of scientific responsibility). She sits on several Boards of national and international projects and has chaired the Scientific Council of the French national cohort of children ELFE (French Longitudinal Study of Children) and the French Society of Human Genetics (2015-2017). Former Member of scientific section of the CNRS, the Scientific Council of the Paul Sabatier University, the Scientific Council of Inserm, the Scientific Council of the Inserm training workshops, the Board of the Rare diseases Foundation, and the expert group of the public health Institute of AVIESAN (The alliance for research in life sciences and health), she is co-pilot of a working group on "Ethics, regulation and society" of the French plan of genomic medicine 2025. She successfully presented the Toulouse's bid to host ESOF (EuroScience Open Forum) 9-14 July 2018, under the auspices of EuroScience and the Federal University in Toulouse, for the first time in France, this city consequently becoming European city of science and Anne Cambon-Thomsen, "ESOF champion".

1. Cambon-Thomsen A, Thorisson Ga, Mabile L on behalf of the BRIF workshop group. **The role of a bioresource research impact factor as an incentive to share human bioresources.** *Nat Genet*, 2011, 43: 503-4
2. Blasimme A, Soulier A Julia S, Leonard S, Cambon-Thomsen A. **Disclosing results to genomic research participants: differences that matter.** *Am J Bioethics*, 2012, 12:10, 20-22
3. Kaye J, Meslin E M., Knoppers B M., Juengst E T., Deschênes M, Cambon Thomsen, A, Chalmers D, De Vries J, Edwards K, Hoppe N, Kent A, Adebamowo C, Marshall P, Kato K. **ELSI 2.0 for Genomics and Society** *Science*, 2012, 336, 673-674
4. Mahalatchimy A, Rial-Sebbag E, De Grove-Valdeyron N, Tournay V, Cambon-Thomsen A, Duguet Am, Taboulet F. **The European Medicines Agency: A Public Health European Agency?** *Medicine and Law Journal*, 2012, Vol. 31, N°1, 25-42
5. Rial-Sebbag E, Cambon-Thomsen A. **Emergence of biobanks in the legal landscape: towards a new model of governance.** *Journal of law and society Vol 39, Number 1, March 2012, 113-30*
6. Ruysen-Witrand A, Constantin A, Cambon-Thomsen A, Thomsen M. **New insights into the genetics of immune responses in rheumatoid arthritis.** *Tissue Antigens*, 2012, Aug;80(2):105-18
7. Anastasova V., Blasimme A., Julia S., Cambon-Thomsen A. **Genomic incidental findings: reducing the burden to be fair.** *Am J Bioethics*, 2013 Feb;13(2):52-4
8. Anastasova V., Mahalatchimy A., Rial-Sebbag E., Antó Boque J.M., Keil T., Sunyer J., Bousquet J., Cambon-Thomsen A. **Communication of results and disclosure of incidental findings in longitudinal paediatric research.** *Pediatr Allergy Immunol* 2013, 24 389–394
9. De Castro, P, Calzolari A., Napolitani, F, Rossi A M., Mabile, L, Cambon-Thomsen, A, Bravo, E; **Open data sharing in the context of bioresources.** *Acta Inform Med.* 2013; 21(4): 291-292
10. Ducournau P., Gourraud Pa., Rial-Sebbag E., Cambon-Thomsen A, Bulle A., **Direct-to-consumer health genetic testing services: what commercial strategies for which socio-ethical issues ?** *Health Sociology Review* (2013) 22(1): 75–87
11. Howard H. C., Swinnen E., Douw K., Vondeling H., Jean-Jacques Cassiman J.J., Cambon-Thomsen A, Borry P. on behalf of PHGENII **The ethical introduction of genome-based information and technologies into public health.** *Public health genomics*, 2013, 16(3):100-9
12. Guedj M., Ballester S., Kamar N., Rostaing L., Donckier V., Cambon-Thomsen A. **Patients' motives for consenting or refusing to participate in a clinical trial in organ transplantation.** *Clinical Transplantation* 2013 Sep 6. 2013 Sep;27(5):724-31
13. Mabile L.; Dagleish R.; Thorisson G. A.; Deschênes M.; Hewitt R; Carpenter J.; Bravo E.; Filocamo M; Gourraud P. A.; Harris J. R.; Hofman P.; Kauffmann F.; Muñoz-Fernandes M. A.; Pasterk M.; Cambon-Thomsen A.; on behalf of The BRIF working group. **Quantifying the use of bioresources for promoting their sharing in scientific research.** *Giga Science*, 2013 May 1;2(1):7
14. Meslin E., Blasimme A., Cambon-Thomsen A. **Mapping the Translational Science Policy 'Valley of Death',** *Clin Transl Med.* 2013 Jul 27;2(1):14. [Epub ahead of print]
15. Mahalatchimy A., Rial-Sebbag E., Duguet A.- M., Taboulet F., Cambon-Thomsen A. **Impact of European Courts' decisions on embryonic stem cells patents: toward new research strategies.** *Nat Biotech*, 2015, Jan 9, 3: 41-43
16. Bravo E., Calzolari A, De Castro P, Mabile L, Napolitani F, Rossi A M, Cambon-Thomsen A, **Developing a guideline for a standardized citation of bioresources in journal articles (CoBRA).** *BMC Medicine*, 2015 <http://www.biomedcentral.com/1741-7015/13/33>
17. Colineaux H, Ruysen-Witrand A., Cambon-Thomsen A. **Genetic markers as a predictive tool based on statistics in medical practice: ethical considerations through the analysis of the use of HLA-B*27 in rheumatology in France.** *Front. Genet.* 6:299. doi: 10.3389/fgene.2015.00299
18. Blasimme A, Anegon I, Concordet JP, De Vos J, Dubart-Kupperschmitt A, Fellous M, Fouchet P, Frydman N, Giovannangeli C, Jouannet P, Serre JI, Steffann J, Rial-Sebbag E, Thomsen M, Cambon-Thomsen A. **Genome Editing and Dialogic Responsibility: "What's in a Name?".** *Am J Bioeth.* 2015 Dec;15(12):54-7
19. Rial-Sebbag, E., Cambon-Thomsen, A. **Governing Biobanks Through a European Infrastructure Ethical, Legal and Social Implications;** In "Ethics, law and governance of biobanking: national, European and international approaches." (Edited by: Mascalon, D). *Book Series: International Library of Ethics Law and Technology.* Springer. 2015, Volume: 14: 139-151
20. Soulier A., Leonard S., Cambon-Thomsen A. **From the arcane to the mundane: Engaging the public in discussing clinical applications of genetic technology.** *New Genetics and Society*, 2016, Volume: 35 Issue: 1 Pages: 1-28
21. MABILE L., DE CASTRO P., BRAVO E., PARODI B., THOMSEN M., MOORE S., CAMBON-THOMSEN A. **Towards new tools for bioresource use and sharing.** *Information Services & Use.* Dec 2016. DOI: <http://dx.doi.org/10.3233/isu-160811>
22. HOWARD H. C., MASCALZONI D., MABILE L., HOUELAND G., RIAL- SEBBAG E., CAMBON-THOMSEN A. **How to responsibly acknowledge research work in the era of big data and biobanks: Ethical aspects of the Bioresource Research Impact Factor (BRIF).** *Journal of Community Genetics* 2017 Sep 25. doi: 10.1007/s12687-017-0332-6)
23. VAN DER WOUDE CH, CAMBON-THOMSEN A, CECCHIN E, CHEUNG KC, LUCIA DAVILA-FAJARDO C, DENEER VH, DOLZAN V, INGELMAN-SUNDBERG M, JÖNSSON S, KARLSSON MO, KRIEK M, MITROPOULOU C, PATRINOS GP, PIRMOHAMED M, SAMWALD M, SCHAEFFELER E, SCHWAB M, STEINBERGER D, STINGL J, SUNDER-PLASSMANN G, TOFFOLI G, TURNER RM, VAN RHENEN MH, SWEN JJ, GUCHELAAR HJ; UBIQUITOUS PHARMACOGENOMICS CONSORTIUM. **Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium.** *Clin Pharmacol Ther.* 2017 Mar;101(3):341-358
24. VAN DER ZANDEN LFM, VERMEULEN SH, OSKARSDOTTIR A, MAURITS JSF, DIEKSTRA MHM, AMBERT V, CAMBON-THOMSEN A, CASTELLANO D, FRITSCH A, GARCIA DONAS J, GUARCH TROYAS R, GUCHELAAR HJ, HARTMANN A, HULSBERGEN-VAN DE KAA C, JAEHDE U, JUNKER K, MARTINEZ-CARDUS A, MASSON G, OOSTERWIJK-WAKKA J, RADU MT, RAFNAR T, RODRIGUEZ-ANTONA C, ROESSLER M, RUIJTENBEEK R, STEFANSSON K, WARREN A, WESSELS L, EISEN T, KIEMENEY LALM, OOSTERWIJK E. **Description of the EuroTARGET cohort: A European collaborative project on Targeted therapy in renal cell cancer-GEtetic- and tumor-related biomarkers for response and toxicity.** *Urol Oncol.* 2017 Aug;35(8):529.e9-529.e16.
25. WHITE SJ, LAROS FJ, BAKKER E, CAMBON-THOMSEN A, EDEN M, LEONARD S, LOCHMÜLLER H, MATTHIJS G, MATTOCKS C, PATTON S, PAYNE K, SCHEFFER H, SOUCHE E, THOMASSEN E, THOMPSON R, TRAEGER-SYNODINOS J, VAN VOOREN S, JANSSEN B, DEN DUNNEN JT. **Critical points for an accurate human genome analysis.** *Hum Mutat.* 2017 Aug;38(8):912-921.